Asia Pacific Influenza Vaccine Market Size & Outlook
Asia Pacific influenza vaccine market, 2018-2030 (US$M)
Related Markets
Asia Pacific influenza vaccine market highlights
- The Asia Pacific influenza vaccine market generated a revenue of USD 1,344.1 million in 2023.
- The market is expected to grow at a CAGR of 8.4% from 2024 to 2030.
- In terms of segment, inactivated was the largest revenue generating vaccine type in 2023.
- Inactivated is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 1,344.1 million |
| Market revenue in 2030 | USD 2,360.7 million |
| Growth rate | 8.4% (CAGR from 2023 to 2030) |
| Largest segment | Inactivated |
| Fastest growing segment | Inactivated |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inactivated, Live Attenuated |
| Key market players worldwide | GSK PLC, Pfizer Inc, Merck & Co Inc, Viatris Inc, AstraZeneca PLC, Sinovac Biotech Ltd, CSL Ltd, Emergent BioSolutions Inc, Vaxess Technologies, Osivax, Emergex Vaccines |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 17.0% of the global influenza vaccine market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,360.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Influenza Vaccine Market Scope
Influenza Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific influenza vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to influenza vaccine market will help companies and investors design strategic landscapes.
Inactivated was the largest segment with a revenue share of 91.35% in 2023. Horizon Databook has segmented the Asia Pacific influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.
The influenza vaccine market in Asia Pacific is expected to grow at the fastest rate over the forecast period due to various factors, such as improving healthcare reforms. Some of the other factors contributing to market growth are increasing geriatric population, improving healthcare infrastructure, and entry of new players.
Some of the major players operating in Asia Pacific market are GSK plc, AstraZeneca, Sanofi, and Serum Institute of India. In addition, owing to the region’s large population, the rate of influenza transmission is also higher. For instance, according to the Singapore Ministry of Health, the country has a higher burden of respiratory infections such as influenza than other diseases.
In addition, presence of international standards set by WHO for production of vaccines in developing economies is expected to drive the market. For instance, the National Regulatory Authority of India and affiliated institutions meet the regulatory guidelines of WHO for vaccines that are imported & exported to other countries.
Reasons to subscribe to Asia Pacific influenza vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific influenza vaccine market databook
-
Our clientele includes a mix of influenza vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific influenza vaccine market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific influenza vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific influenza vaccine market size, by country, 2018-2030 (US$M)
Asia Pacific Influenza Vaccine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
